ReviewJournal of neurology2025
Camptocormia in Parkinson's disease: state of the art and future directions.
Review in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Camptocormia is a frequent axial postural deformity in Parkinson's disease (PD) that is prevalent in up to 18% in the PD population. Camptocormic PD patients have a lower quality of life and higher risks of falls, back pain and spondylarthrosis. Camptocormia is probably induced by brain changes caused by PD. Despite the myopathic changes in camptocormic PD patients' spine muscles and camptocormia's clinical similarity with dystonic postures, its pathophysiology seems to be different from myopathy and dystonia. The exact pathogenesis is however unclear. There is no consensus for treatment of PD-related camptocormia, although some nonpharmacological (e.g., backpack weight, back extensors and physiotherapy), pharmacological (e.g., levodopa, istradefylline and botulinum toxin) and surgical approaches (surgical corrections and deep brain stimulation) were elaborated upon with variable effects. There are still many gaps in data regarding clinical predictors, pathophysiology, the treatment and prevention of camptocormia. Multicenter studies (particularly on nonpharmacological therapy, on preventing strategies, and on favorizing factors) are needed. We identified an unexpectedly limited number of publications on camptocormia in PD. As of August 2025, the search strategy with MeSH terms related to camptocormia, on PubMed returned only 220 results. After screening, only 138 of the titles and abstracts were relevant to the topics. Of all these publications, only 27 (19.6%) were reviews, and more than half of which (15 reviews) focused on some characteristics of camptocormia (e.g., surgical treatment, deep brain stimulation, and prevalence or etiology) but did not elucidate on all its complex aspects. The present narrative review aims to describe different aspects of camptocormia ranging from its prevalence to the pathophysiology and treatment possibilities and provide a comprehensive image of this disorder.
Indexed as
Identifiers
40975851What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.